Skip to main content

Table 1 Baseline characteristics of the subjects

From: Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial

 

SQT (n = 195)

PBAT (n = 195)

p-value

Gender, n (%)

  

0.184

 Male

103 (52.8)

117 (60.0)

 

 Female

92 (47.2)

78 (40.0)

 

Age (mean ± SD), year

53.1 ± 12.6

53.6 ± 13.2

0.697

BMI, kg/m2

23.5 ± 3.1

23.9 ± 3.4

0.328

Smoking, n (%)

38 (19.5)

36 (18.5)

0.897

Alcohol, n (%)

75 (38.5)

72 (36.9)

0.835

Endoscopic finding, n (%)

   

 Normal

10 (5.1)

11 (5.6)

1.000

 Atrophic gastritis with or without intestinal metaplasia

43 (22.1)

31 (15.9)

0.155

 Other gastritis

12 (6.2)

16 (8.2)

0.556

 Gastric ulcer

47 (24.1)

43 (22.1)

0.718

 Duodenal ulcer

15 (7.7)

20 (10.3)

0.479

 Gastric ulcer + Duodenal ulcer

4 (2.1)

7 (3.6)

0.541

 EMR, ESD for dysplasia or EGC

16 (8.2)

18 (9.2)

0.858

 MALToma

1 (0.5)

0 (0.0)

1.000

 Reflux esophagitis

1 (0.5)

3 (1.5)

0.615

 Others

10 (5.1)

7 (3.6)

0.620

  1. SQT sequential therapy, PBAT quadruple therapy consist of pantoprazole, bismuth, amoxicillin, and tetracycline, BMI body mass index, EMR endoscopic mucosal resection, ESD endoscopic submucosal dissection, EGC early gastric cancer, MALToma mucosal associated lymphoid tissue lymphoma